The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said on 23 February 2021 that Mexico, the first country in North America to approve Russia's Sputnik V COVID-19 vaccine, has received its first batch of the vaccine, CNN reported on Tuesday.
In a statement, the RDIF said: "On 3 February 2021, the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the emergency use authorisation procedure without additional clinical trials in the country."
Kirill Dmitriev, CEO of the RDIF, said: "it is a significant breakthrough in Russia's efforts to fight COVID-19 and clearly shows that saving lives is above politics."
According to figures from the RDIF, which oversees global distribution and sales of the vaccine, Russia's Sputnik V COVID-19 vaccine has now been approved for use in more than 30 countries and is one of the world's most pre-ordered vaccines, with at least 50 countries, from Argentina to the Philippines, ordering nearly 2.5 billion doses so far.
A tally by Johns Hopkins University has revealed that Mexico has the third highest death toll in the world, behind the US and Brazil, with more than 180,000 deaths.
4basebio introduces enzymatic ssDNA platform for gene editing applications
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
GC Biopharma secures first Latin American approval for BARYCELA Inj.
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform